Healthcare
InspireMD, Inc.(NSPR)
Live Price
Offline$0.71
-4.05% today
1Y Change
-68.71%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $50.00M
- Revenue Growth
- +28.1%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
InspireMD, Inc. (NSPR) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $0.71 and down 68.7% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +28.1%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue +28.1%, EPS 0.0%, free cash flow -58.0% with operating margin -552.6% and ROIC -84.5%. Valuation sits in the middle of the pack at price/sales 6.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines NSPR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+28.1% vs +7.6% peer median
Operating Margin
Below sector median
-552.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 8, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is +28.1% and EPS is 0.0%, while operating margin sits near -552.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -11.1% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 8, 2026 | โ | +8.7% | -8.7% | -28.7% |
2026 Mar 18, 2026 | +36.4% | -4.5% | -1.1% | -24.6% |
2025 Nov 4, 2025 | +0.0% | -0.9% | -23.5% | -10.3% |
Benchmark Edge
NSPR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NSPR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NSPR Max Drawdown
-74.87%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NSPR and SPY.
Company Overview
InspireMD, Inc.
NASDAQ Capital Market
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
- Leadership
- Marvin L. Slosman
- IPO Date
- Apr 12, 2011
- Employees
- 85
- Street Address
- 4 Menorat Hamaor Street
- Mailing
- Miami, 6744832
- Region
- Miami, IL
- Reporting Currency
- USD
- Investor Line
- 888 776 6804
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 6.0
- Price/Book
- 1.5
Growth
- Revenue
- +28.1%
- EPS
- 0.0%
- Free Cash Flow
- -58.0%
Profitability
- Gross Margin
- 29.5%
- Operating Margin
- -552.6%
- Net Margin
- -543.3%
- ROE
- -116.2%
- ROIC
- -84.5%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 5.74
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.